What percentage of parotid tumors are pleomorphic adenomas?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Percentage of Pleomorphic Adenomas in Parotid Tumors

Pleomorphic adenomas account for 60-70% of all benign parotid tumors, making them the most common type of parotid gland tumor. 1, 2

Epidemiology and Classification of Parotid Tumors

  • The majority (70-80%) of parotid tumors are benign 1
  • Among benign tumors, pleomorphic adenomas are the most common (60-70%) 1
  • Warthin tumors are the second most common benign parotid tumors (5-12%) 1
  • Malignant tumors represent 20-30% of parotid neoplasms 1
    • Common malignant types include mucoepidermoid carcinoma, adenoid cystic carcinoma, lymphoma, and acinic cell carcinoma 1

Clinical Characteristics of Pleomorphic Adenomas

  • Typically present as slow-growing, painless masses 2
  • Most commonly affect patients in the fourth to sixth decade of life 2
  • Show a female predominance 2
  • Usually located in the superficial lobe of the parotid gland (75%) 3
  • Can occasionally occur in accessory parotid tissue (found in 10-56% of individuals) 4

Histopathological Features

  • Pleomorphic adenomas can be classified into three subtypes 5:
    • Myxoid (stroma-rich) type: 51% of cases
    • Cellular type: 35% of cases
    • Classic type: 14% of cases
  • Most (97%) have areas with thin capsules (<20 μm) regardless of subtype 5
  • Myxoid subtypes frequently (71%) show focal absence of encapsulation 5
  • Approximately 25% of all pleomorphic adenomas contain abnormalities such as satellite nodules or pseudopodia 5

Management Considerations

  • Surgical excision is the treatment of choice 2, 5
  • Due to capsular abnormalities and risk of recurrence, enucleation or local dissection is not recommended 5
  • For low-grade, early-stage (T1-T2) tumors, partial superficial parotidectomy with adequate margins is recommended 1, 6
  • Recurrence rates following superficial parotidectomy are reported to be around 4% 3
  • Retrograde partial superficial parotidectomy has shown advantages over classical superficial parotidectomy in terms of surgical time, preservation of healthy tissue, and lower risk of facial nerve injury 2

Imaging and Diagnosis

  • MRI with and without IV contrast is the preferred imaging modality for comprehensive assessment of parotid tumors 6
  • Fine needle aspiration biopsy with potential intraoperative frozen section helps determine tumor type and grade 6
  • Frozen sections have 99% accuracy for identifying neoplastic lesions but only 59% accuracy for malignant tumor typing 6

Understanding the high prevalence of pleomorphic adenomas among parotid tumors is essential for clinical decision-making and surgical planning in patients presenting with parotid masses.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Superficial parotidectomy versus retrograde partial superficial parotidectomy in treating benign salivary gland tumor (pleomorphic adenoma).

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2010

Guideline

Management of Deep Lobe Parotid Tumors

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.